The Trump administration reportedly is nearing completion of a new immigration rule that healthcare providers and plans fear will harm public health and their ability to serve millions of low-income children and families.
As scrutiny tightens on drug middlemen and the significance of their role in spiking drug costs within Medicare Part D, health insurers are hitting back with data that show the most expensive drugs offer the lowest rebates.
Ohio's Medicaid department is directing its managed-care organizations to quit their contracts with pharmacy benefit managers because of opaque pricing practices and strike up new arrangements with transparent vendors.
In an effort to encourage ACOs to take on downside risk earlier, it plans to end the Track 1 upside-risk-only model.
It's hard to believe it, but for many kids, summer will come to an end in the coming weeks. As parents bulk up on school supplies, it's also important to remember a visit to the doctor's office for immunizations. After all, August is National Immunization Awareness Month.
While Roe v. Wade will be the hot-button issue in the fight over the next Supreme Court justice, the high court could continue to reshape the broader healthcare landscape if cases on the Affordable Care Act and Medicaid work their way through the courts.
A special National Institutes of Health oversight panel will no longer review all gene therapy applications and will instead take on a broader advisory role, as the treatment quickly becomes an established form of medical care with no extraordinary risks.
A major player in 340B drug discount reforms, Rep. Chris Collins (R-N.Y.) can't serve on the House Energy & Commerce Committee, a key health committee, until federal charges of insider trading are resolved.
The owners of a New Hampshire provider stopped caring for 16 veterans as of Friday because they were unable to get about $60,000 in bills paid by the Veterans Affairs Department.